FLGT News and Press, Fulgent Genetics Inc. From 03/08/22

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that its Board of Directors...

Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer HelioLiver significantly outperforms other clinically available tools in both early-stage and overall HCC detectio...

Once again, the company exceeded quarterly expectations on the flare-up of another pandemic wave. However, their core revenue, which was growing 134% last year is going to slow down to grow 28% this year, that's a huge slowdown which we didn't see coming. It's still a great compan...

Epic Sciences is collaborating with Fulgent Genetics (FLGT -5.9%) to deliver DefineMBC profiling results for patients with metastatic breast cancer (MBC). The partnership links Fulgent's CAP/CLIA certified next generation sequencing services with Epic's cell analysis platform as part of ...

EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics' expertise in high-volume testing pow...

Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT) Q4 2021 Earnings Call Feb 23, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Larry Weiss - Chief Medical ...

Shares of Fulgent Genetics (NASDAQ:FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines. Net income fell 37% to ~104.3M compared to the prior-year period. Diluted earnings per share went from $6.16 to $3.34. Net revenue in the qua...

The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Fulgent Genetics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Fulgent Genetics (NASDAQ:FLGT) announced a strategic investment in Spatial Genomics, a developer of sequential fluorescence in situ hybridization (seqFISH) technology. FLGT is investing up to $40M to lead Spatial's series A financing, which totals ~$56M and also includes investments by 12 Wes...